Medicinal composition for treating macular degeneration

Abstract

The invention discloses a medicinal composition for treating macular degeneration. The medicinal composition for treating the macular degeneration comprises eight kinds of medicaments, such as astragalus, Chinese angelica, Indian buead, thunberg fritillary bulb and the like. The medicinal composition is prepared to be pharmaceutically acceptable formulations such as decoction, tablets, capsules, pills, oral liquid preparations, injection and the like by adding the conventional auxiliary materials and by the conventional process. The medicinal composition can improve and stabilize vision of age-related macular degeneration (AMD) patients, can promote bleeding absorption and can reduce macular area choroidal neovascularization (CNV) fluorescence leakage. Symptom and disease differentiation-based treatment embodies the advantage of the traditional Chinese medical science in the aspect of improving vision function. Due to the combination of fundus fluorescein angiography (FFA) examination, pathological examination and choroid blood vessel stretched preparation, the CNV can be evaluated well. According to the observation on morphological methods such as model FFA after medicament intervention, pathology, choroid blood vessel stretched preparation and the like, the medicinal composition has a good effect of inhibiting the CNV of laser induced brown Norway (BN) rats and has a certaineffect of inhibiting or stabilizing the growth of the CNV.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating macular degeneration. Background technique [0002] Age-related macular degeneration (age-related macular degeneration, AMD) is more common in the elderly over 55 years old. AMD is a degenerative disease of the retinal pigment epithelium (RPE), Bruch's membrane, and choroidal capillaries in the macular area. AMD is divided into two types: dry and wet. Especially in wet AMD, the formation of subretinal choroidal neovascularization (CNV) in the macula is the root cause of blindness in this disease. [0003] AMD is an intractable disease in ophthalmology, its pathogenesis is still unclear, and the current treatment methods are all exploratory therapies. Mainly include: photodynamic therapy, transpupillary thermotherapy, laser photocoagulation, radiotherapy, surgical treatment, drug treatment, gene therapy, traditional Chinese medicine treatm...

AI Technical Summary

Problems solved by technology

Photodynamic therapy is currently proven to be more effective treatment, but its curative effect is based on not continuing to reduce visual acuity as the evaluation standard, and this therapy is expensive and requires repeated treatment; laser therapy for photocoagulation of neovascularization below the fovea, It usually leads to a direct decline in central vision, and the recurrence rate of laser photocoagulation treatment of neovascularization is also high; the current focus of Western medicine drug therapy is on the research and development of anti-neovascular endothelial growth factor inhibitors, such as Pegaptanib Sodiuml (pegatanib sodium ) and Bevacizumab, etc., but are still in clinical trials

[0004] From the above, it can be seen that there is no satisfactory treatment method in Western medicine, and Chinese medicine has certain advantages in the exploratory treatment of this disease.

Images